HeartBeam Inc. (NASDAQ: BEAT), a medical-technology company specializing in advanced electrocardiogram (ECG) solutions, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. According to the report, HeartBeam ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. This recognition highlights the company’s growing influence in the next generation of cardiac monitoring technology.
HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. In doing so, HeartBeam is addressing one of modern medicine’s most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, and ischemia is a future goal.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement.
The recognition by PatentVest is significant for HeartBeam as it validates the company’s innovative approach and positions it as a key player in the portable cardiac diagnostics market. With a strong intellectual property portfolio and a clear focus on expanding access to high-quality cardiac monitoring, HeartBeam is poised to make a substantial impact on how arrhythmia and potentially ischemia are detected and managed.
For more information about HeartBeam, visit HeartBeam.com. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
